Sun, Taro's settlement with end payers in US generic drug suit gets final nod
MLex Summary: Sun Pharmaceutical and Taro Pharmaceutical’s $200 million settlement to resolve US antitrust claims from end payor plaintiffs accusing them of fixing the prices of generic pharmaceuticals has been granted...To view the full article, register now.
Already a subscriber? Click here to view full article